ERDAFITINIB for Neoplasm: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 28 adverse event reports in the FDA FAERS database where ERDAFITINIB was used for Neoplasm.
Most Reported Side Effects for ERDAFITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 255 | 23.1% | 255 | 8 |
| Off label use | 86 | 7.8% | 5 | 16 |
| Diarrhoea | 75 | 6.8% | 5 | 22 |
| Stomatitis | 58 | 5.2% | 6 | 15 |
| Fatigue | 45 | 4.1% | 4 | 13 |
| Onycholysis | 44 | 4.0% | 8 | 15 |
| Disease progression | 41 | 3.7% | 8 | 14 |
| Dry mouth | 41 | 3.7% | 3 | 12 |
| Nail disorder | 40 | 3.6% | 1 | 4 |
| Hyperphosphataemia | 39 | 3.5% | 4 | 11 |
| Dry eye | 38 | 3.4% | 4 | 3 |
| Mucosal inflammation | 35 | 3.2% | 5 | 5 |
| Decreased appetite | 33 | 3.0% | 4 | 17 |
| Drug ineffective | 33 | 3.0% | 8 | 4 |
| Nail discolouration | 31 | 2.8% | 1 | 11 |
Other Indications for ERDAFITINIB
Product used for unknown indication (641)
Transitional cell carcinoma (168)
Bladder cancer (74)
Cholangiocarcinoma (19)
Metastatic carcinoma of the bladder (18)
Transitional cell carcinoma metastatic (18)
Breast cancer metastatic (13)
Bladder transitional cell carcinoma (9)
Plasma cell myeloma (8)
Urethral cancer (8)
Other Drugs Used for Neoplasm
BEVACIZUMAB (502)
ATEZOLIZUMAB (404)
CYCLOPHOSPHAMIDE (385)
CARBOPLATIN (283)
PACLITAXEL (267)
NIVOLUMAB (219)
OXALIPLATIN (185)
PEMBROLIZUMAB (173)
LENALIDOMIDE (171)
DOXORUBICIN (150)